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A b s t r a c t  
The enhanced permeability and retention (EPR) effect is a unique phenomenon of solid tumors 
related to their anatomical and pathophysiological differences from normal tissues. In solid tumors, 
angiogenesis leads to high vascular density. Large gaps exist between endothelial cells in tumor 
blood vessels, which lead to selective extravasations and retention of macromolecular drugs. This 
EPR effect served as a basis for development of macromolecular anticancer therapy. There are 
various factors, which lead to a significantly increased EPR effect and enhanced antitumor drug 
effects as well. This review discusses the unique anatomy of tumor vessels, molecular mechanisms 
of factors related to the EPR effect and the role of the EPR effect in the intra-tumoral delivery of 
protein and peptide drugs, macromolecular drugs and drug-loaded long-circulating nanocarriers. 
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Introduction 
The enhanced permeability and retention (EPR) effect was first 
reported by Matsumura and Maeda in 1986 [1]. It is a phenomenon 
wherein certain sizes of molecules (macromolecular bioactive 
compounds or nanoparticles) accumulate in tumor tissue much 
more than they do in normal tissues. This phenomenon can be 
generally explained as that, so as to grow very fast, tumor cells 
must stimulate the production of new blood vessels. EPR effect is 
an exceptional property of solid tumors associated to their 
pathophysiological and anatomical variations from normal tissues. 
The accumulation and retention of macromolecules are very much 
improved in tumor tissue as compared to those in normal tissue. 
This phenomenon is mainly pertinent only to macromolecules and 
particles and not to low-molecular-weight compounds [2].  
It is very well-established phenomenon that under certain 
pathological condition (inflammation/hypoxia and tumors) the 
endothelial lining cells of the blood vessel turn into more permeable 
than the normal state. Consequently, particles ranging from ~50 to 
500 nm in size, leave the vascular bed and gather inside the 
interstitial space. This phenomenon has been demonstrated in a 
variety of tumors [3]. If these particles are loaded with a bioactive 
molecules or anti-cancer drugs, the bioactive molecule can be 
eventually delivered from the particles to tumor [4]. The leaky tumor 
vasculature permits macromolecules and nanocarriers to come into 
the tumor interstitial space, whereas due to the compromised 
lymphatic filtration they stay there [5]. On the other hand, “small” 
low-molecular weight bioactive agents are not retained and return 
to the circulation by diffusion [6]. EPR-mediated drug delivery have 
been considered as an effective way to deliver chemotherapeutic 
drugs into the tumors, mainly macromolecular drugs and drug-
loaded nanocarriers [7]. EPR effect may result in macromolecules 
accumulation at much higher concentrations in tumor tissues as 
compared to normal tissues. The majority of stealth nanocarriers 
accumulate in tumor tissue at a concentration 5–10 times higher 
than that of plasma after 24 h of intravenous injection, in addition 
more than 10 times higher than that of normal tissue [8].  
Macromolecular delivery systems have been explored for the 
delivery of antineoplastic agents using EPR effect. The concept 
behind utilization of drug-macromolecule conjugates is to improve 
distribution of the drug [9, 10]. Similarly, nanocarriers, such 
polymeric nanoparticles have been explored tremendously for drug 
delivery to tumors via passive accumulation using EPR effect. This 
review shade light on the distinctive composition of tumor vessels, 
molecular factors related to the EPR effect, and the utility of the 
EPR effect in the intra-tumoral delivery of nanocarriers,. 
 
Distinctive Characteristics of Tumor Blood Vessels 
 
The EPR effect is a exceptional phenomenon of solid tumors 
associated to their anatomical and pathophysiological variations 
than normal tissues. 
 
Morphology of tumor blood vessels 
 
Unlike normal tissues and organs, the solid tumors show 
hypervasculature, particularly when tumors are small, some 
exceptions being pancreatic, prostate and large metastatic liver 
cancers [11]. Tumor angiogenesis is most important aspect that 
causes rapid tumor growth, which begin as the tumor diameter 
becomes approximately 0.8–1.0 mm [12]. As shown in Figure. 1, 
the newly formed tumor blood vessels generally have an 
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cells with large fenestrations, lack of a smooth muscle layer, wide 
lumen, asymmetrical vascular configuration as well as impaired 
receptors for angiotensin II (AT-II) [13, 14]. Additionally, in these 
vessels blood flow direction is also irregular or incon
 
Blood vasculature and tumor blood flow  
 
The arteriole–venule (A–V) pressure difference and flow resistance 
determines the blood flow within a tissue. There are very few 
arteries/arterioles in tumor periphery and blood vessels in the tumor 
interior are mainly veins/venuoles. Thus, the A
difference is insignificant in the central region but greater in the 
tumor periphery. This to a degree clarifies the higher blood flow in 
 
                                                      Figure. 1: Anomalous structural of newly formed tumor blood vessels.
The intra-tumoral vasculature heterogeneities play a major role in 
uneven anti-cancer drug distribution within solid tumors. It has been 
reported that in transplanted rodent tumors, the pore size of tumor 
microvessels differs from 100 to 700 nm in diameter based on the 
anatomical location. The enhanced vascular permeability and 
dilatation in tumors is attributed to elevated levels of vasoactive and 
growth factors (vascular endothelial growth factor, nitric oxide, 
bradykinin, basic fibroblast growth factor) [16]. Due to leaky
the key trail of macromolecules transport across tumor 
microvascular wall is by extravasation via diffusion and/or 
convection through the discontinuous endothelial junctions. 
Extravasation of molecules is related to fluid exchange across 
vasculature wall, which is based on the hydrostatic pressure 
gradient amid intravascular space (i.e., microvascular pressure or 
MVP) and interstitial space (i.e., interstitial fluid pressure or IFP) and 
the osmotic pressure gradient due to variations in protein lev
[18].  
 





the periphery and the lower blood flow in the center of a tumor
Blood vessel distribution within a tumor depends on
and the locations within a tumor. Small tumors are perfused by 
vasculature derived from adjacent host tissues, while bigger tumors 
are typically accompanied by newly formed microvessels [16]. A 
solid tumor encompasses three regions: (a) ava
with no vasculature, (b) stably perfused region containing many 
venous vessels and few arteriolar vessels, and (c) semi
region containing capillaries. Vascularization is inversely correlated 
to tumor size wherein bigger tumors





Impaired lymphatic clearance 
 
Lymphatic vessels are more permeable to fluid and solutes as 
compared to blood capillaries and widely distributed throughout the 
body. The key role of the lymphatic system is to return the interstitial 
fluid to the blood circulation [19]. Lymphatic clearan
tissue and lymphatic metastasis tumor tissues typically lack efficient 
lymphatic drainage, which decreases clearance of nanocarriers 
from tumor interstitium [20].  Lymphatic system is the most 
important route for metastasis of tumor cells into 
Lymphatic metastasis is one of the most frightening consequences 
of cancer progression, and its control is critically important [21]. 
Maeda et al. have shown that evans blue
injected i.v. into tumor-bearing mice it accu
the tumor for above a week, conversely it was gradually cleared 
from non-tumor tissue by normal lymphatic function [22].
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The Factors Which Affect EPR Effect  
 
Tumors overexpress many permeability-enhancing factors, which 
contribute to an enhanced EPR effect. It is also affected by many 
pathophysiological factors involved in enhancement of the 
extravasation of macromolecules. Few factors are given below.  
Active angiogenesis and high vascular density 









Augmented Tumor Delivery of Polymer Conjugates and 




Polymer conjugates are nano-sized hybrid constructs that covalently 
join a bioactive molecule with a polymer. This ensure efficient 
delivery and availability of bioactive molecule to the required 
intracellular compartment [23]. It has been demonstrated previously 
that polymer conjugation uphold tumor targeting by the EPR 
effect and, allows lysosomotrophic drug delivery. Polymer 
conjugates have the potential to improve the treatment of drug-
resistant tumors with reduction in toxicity [24]. These type of 
polymer-drug multicomponent conjugates have been already 
transferred to clinics [25]. Polymer-protein as well as polymer-drug 
conjugates were employed as a one of the foremost classes of 
anticancer nanomedicines [24]. Polymer conjugates offer a lot of 
advantages with regards to EPR effect such as Stealth character (if 
conjugated with PEG), reduced immunogenicity, prolonged 
circulation and thus half life, enhanced stability and higher cellular 
uptake [26, 27]. In addition EPR effect, intracellular uptake of 
polymer-drug conjugated can be enhanced by exploiting receptor-
mediated endocytosis wherein targeting ligands can be attached to 




EPR based tumor targeting necessitates drug delivery systems to 
be long-circulating so that a sufficient level can  accumulate in the 
target. Modifying surface of the nanocarriers with water-soluble 
polymers (e.g. PEG) is most common way to keep them in the blood 
for long time [29, 30]. The size and long circulation of a nanocarrier 
play very crucial role in EPR-mediated drug delivery [31, 32]. 
Similarly, properties of delivery system like molecular weight, 
surface characteristics and surface charge also play very important 
role for good EPR effect. 
Delivery systems that have molecular weight of more than 30 KDa 
can escape quick renal clearance and keep circulating in blood but 
smaller molecules that readily redistribute to blood circulation via 
diffusion and/or convection [33]. Likewise, The size of the total 
complex should not be more than 200 nm. This is because the 
delivery system must be able to penetrate the openings or fenestrae 
of the endothelial cells of the capillaries. The nature of the surface 
of the delivery system should be hydrophilic to avoid removal by the 
monophasic phagocytic system (MPS) [34]. In addition, surface 
charge of the drug delivery system has a positive or negative 
charge or is neutral in charge indicates for how long it can circulate 
in the blood [35, 36], because the luminal endothelial membrane in 
vessels is negatively charged and therefore can be targeted by 
cationic NP through electrostatic interactions [37-39]. This approach 
leads to more rapid and more extensive NP extravasation and 
retention in tumors relative to passive targeting via the EPR effect 




Stealth long-circulating nanocarriers, for example polymeric 
nanoparticles, are competent of accumulating in different 
pathological regions using the EPR effect owing to altered 
vasculature, and have been exploited much for anti-cancer drug 
delivery to tumors by means of passive accumulation. Polymeric 
nanoparticles exhibit dose-independent, log-linear and non-
saturable kinetics with increased bioavailability [41, 42]. 
Hydrophobically modified glycol chitosan (HGCs) nanoparticles 
loaded with cisplatin, effectively accumulated in tumor tissues in 
tumor-xenografted mice, on account of prolonged circulation and 
EPR effect [43]. PEG conjugation on nanoparticles reported to 
prolonged half life in the blood compartment which allowed 
nanoparticles to selectively extravasate in pathological areas such 
as tumors or inflamed regions [44]. Mitraa  et al [45] reported 
improved therapeutic efficacy of doxorubicin coupled dextran (DOX-
DEX) when encapsulated in biocompatible, biodegradable and long 
circulating hydrogel nanoparticles of 100±10 nm size, which favored 
the EPR effect. Etame et al [46] reported gold nanoparticles 
(AuNPs) with potential relevance for brain tumor targeting wherein 
they designed and characterized AuNPs having diverse particle 
sizes of the core (4–24 nm) and PEG chain lengths (Mw 1000–
10,000 Da). The authors established that the permeation properties 
of the nanoparticles are size-dependent relating to the core particle 
size and PEG chain length. Their result suggested that smaller PEG 
chain formulations (e.g. PEG 1000 and 2000) were more easily 
transported as compared to higher PEG chain formulations (e.g. 
PEG 5000 and 10,000).  
Nanoparticles are proficient to deliver therapeutic as well as imaging 
contrast agents safely to tumors for theranoustic application using 
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EPR effect, wherein both can be encapsulated in the core of 
nanoparticles for dual purpose [47]. Magnetic nanoparticles (MNPs) 
also own exceptional magnetic properties with the ability to work at 
the cellular and molecular level making them an attractive platform 
as contrast agents for MRI and as drug delivery carriers [48]. Hai et 
al [49] anticipated the co-delivery  approach to reduce the quantity 
of each drug and to accomplish the synergistic effect for cancer 
therapies. The idea was to overcome the drawback of development 
of drug resistance and high toxicity. NPs from an amphiphilic 
copolymer PLGA-mPEG was used to co-deliver hydrophilic 
doxorubicin and hydrophobic paclitaxel. Cellular uptake studies 
demonstrated that both drugs were efficiently taken up by the cells 




Liposomes, or phospholipid vesicles, have been well renowned as a 
prospective drug delivery carrier for more than three decades. 
These nanocarriers display better extravasation and accumulation 
in solid tumors owing to enhanced endothelial permeability and 
reduced lymphatic drainage (EPR effect) [50]. These provide a 
controlled release carrier as well as a biocompatible solubilizing 
nanocarrier for inadequately soluble drugs. On account of their size, 
which varies from 50 to 250 nm can be used for the systemically 
administered wherein they exhibit some distinctive pharmacokinetic 
characteristics [51, 52]. These include non-recognition from the 
RES resulting in long circulation time with less hepatic as well as 
splenic distribution [53]. Liposomes have shown exceptional 
qualities for improvement of drug loading, as stealth liposomes [54], 
pH-sensitive liposomes for cytosolic drug delivery, cationic 
liposomes for nucleic acid delivery, targeted liposomes for selective 
delivery to specific tumor [55] and temperature-responsive 
liposomes for hyperthermia [56].  
Plasma proteins are reported to adsorbed easily on the surface of 
conventional liposome resulting in recognition by the RES, and 
eliminated from the body [57]. PEGylated liposomes with extended 
circulation time in the blood are commonly called “stealth” or 
sterically stabilized liposomes [58, 59]. PEG-liposomes escape from 
the wide gaps between neighboring endothelial cells and widely 
penetrate into the interstitial space of tumor. Their specificity has 
been distinctly enhanced by using ligands. Among the different 
techniques for active targeting, immunoliposomes by means of an 
antibody as targeting ligand have attracted a lot of attention. PEG 
coating can also be detached using local pathological conditions 
(e.g. lower pH of tumors) [60, 61].  
Mayer et al. [62] have examined the application of liposomes as a 
co-delivery vehicle for combinations of cisplatin/daunorubicin, 
daunorubicin/cytarabine, and irinotecan/fluoxuridine. Long 
circulating stealth formulation of DOX has exhibited increased solid 
tumor accumulation because of the EPR effect with decreased 
cardiac toxicity relative to the free DOX [54]. In an another study, 
co-encapsulation of DOX and verapamil in liposomes was shown to 
be highly effective against multidrug resistant cancer cells [63]. DOX 
loaded PEG-coated liposomes have demonstrated very high 
efficiency in EPR-based tumor therapy and strongly reduces the 
side effects [64, 65]. Clinical data also suggested the striking effect 
of DOX-PEG-liposomes against hepatocellular carcinoma [66]. 
PEGylated liposomes loaded with rapamycin avoided the major 
sequestration of rapamycin into the erythrocytes [67]. Photodynamic 
therapy (PDT) is a rapidly-developing technique for the 
management of superficial tumors. In PDT, liposomes have been 
used as drug carriers as well as enhancers both [68]. Vascular 
permeability inside the tumor significantly influence the 
accumulation of PEG liposome in tumor and is one of the vital 
components for in vivo anti-tumor effectiveness of DOX-PEG-
liposomal [69]. Man et al [70]  reported treatment of trastuzumab-
insensitive breast cancer by development of a liposome formulation 





Dendrimers are well-organized, highly branched nanostructures 
which provide a series of flexible chemical alteration for a variety of 
purposes [71-73]. The biological fate of dendrimer loaded drugs can 
be considerably changed owing to their physicochemical properties. 
Pharmacokinetics play an key function for successful in vivo 
application and clinical translation of dendrimer [74]. Dendrimer 
nanoconstructs explore innovative promising class of nanocarriers 
as delivery and imaging agent via both passive and active targeting 
approaches. PEGylation can also increase circulation time of 
dendrimer [75], Dendrimer have resulted in prolonged plasma 
exposure of DOX as compared to f free drug. In addition, tissue 
biodistribution profiles of PEGylated dendrimer revealed more 
effective tumor targeting of drug. The noteworthy antitumor activity 
of dendrimer–DOX was due to the ability of the dendrimer to 
favorably modulate the pharmacokinetics of loaded DOX [76]. The 
PEGylated dendrimers with the higher generation and the longer 
PEG led the greater blood retention [77]. Okuda et al [78] evaluated 
biodistribution characteristics of PEGylation dendrimers in both 
normal and tumor-bearing mice and demonstrated effective 
accumulation in tumor tissue via the EPR effect. Dendrimers and 
dendrimer-based therapeutics are outstanding candidates in 
therapy and diagnostics field as more and more biological systems 
have benefited from these starburst molecules. Dendrimer 
conjugates have huge potential to serve as an innovative 
multifunctional delivery and imaging agent for the treatment and 














Carbon nanotubes (CNTs), have turn out to be a popular 
nanocarrier due to their unique physicochemical properties for 
cancer diagnosis and therapy. They are considered to be very 
promising nanomaterials for delivering drugs or small therapeutic 
molecules [80]. In the last few years, CNTs have been exploited for 
cancer treatment modality, including lymphatic targeted 
chemotherapy, photodynamic therapy, drug delivery, thermal 
therapy as well as gene therapy [81]. Zhuang et al (2008) reported 
that, PEGylated single-walled carbon nanotubes (SWNT) showed 
higher efficacy in suppressing tumor growth, due to prolonged blood 
circulation and EPR effect [82]. Cheng et al  [83] reported 
PEGylated MWCNTs as drug carrier to overcome multidrug 
resistance. Their results also concluded that PEGylated MWCNTs 
are efficient drug carriers to conjugate drugs for overcoming MDR in 
cancer treatment. Owing to their unique surface properties, large 
surface areas and needle-like shape, can transport a higher amount 
of bioactive agents, including DNA and RNA, to the target disease 
sites [84]. Functionalized carbon nanotubes also exhibit distinctive 
properties that enable a range of biomedical applications, including 
the diagnosis and treatment of cancer [85]. Carbon nanotubes can 
be also used as a pro-drug by attaching pro-drugs to different parts 
of carbon nanotubes, wherein once the drug-loaded nanotube is 
into a cancer cell via EPR effect, the pro-drug is metabolized into its 




The EPR effect is the exclusive and most critical event that is 
occurring in tumor tissues, which accounts via pathophysiological 
and anatomical features of tumor blood vessels. Moreover, vascular 
mediators, such as NO, BK and PGs critically affect EPR effect. 
Owing to EPR effect, macromolecular anticancer drugs are getting 
additional attraction in cancer chemotherapy as compared to 
conventional chemotherapy which can certainly improve therapeutic 
efficacy and reduce adverse effects. EPR effects is observed 
solitary for polymer-drug conjugates as well as nanocarriers of 
specific size. Nowadays it turn out to be possible to accumulate 
nanocarriers selectively in tumor either by altering vascular 
mediators or by increasing the systemic blood pressure via infusion 
of angiotensin II. This enhanced vascular permeability of tumor 
tissue is the most important factor to be considered for development 
for highly selective targeting to the specific desired tumors. 
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